• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过同源蛋白加强,编码溃疡分枝杆菌(mycolyl-transferase Ag85A)的种特异性 DNA 疫苗的保护效力得到提高。

Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.

机构信息

Mycobacterial Immunology, IPH-Pasteur Institute Brussels, Brussels, Belgium.

出版信息

PLoS Negl Trop Dis. 2008 Mar 19;2(3):e199. doi: 10.1371/journal.pntd.0000199.

DOI:10.1371/journal.pntd.0000199
PMID:18350112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2265439/
Abstract

Vaccination with plasmid DNA encoding Ag85A from M. bovis BCG can partially protect C57BL/6 mice against a subsequent footpad challenge with M. ulcerans. Unfortunately, this cross-reactive protection is insufficient to completely control the infection. Although genes encoding Ag85A from M. bovis BCG (identical to genes from M. tuberculosis) and from M. ulcerans are highly conserved, minor sequence differences exist, and use of the specific gene of M. ulcerans could possibly result in a more potent vaccine. Here we report on a comparison of immunogenicity and protective efficacy in C57BL/6 mice of Ag85A from M. tuberculosis and M. ulcerans, administered as a plasmid DNA vaccine, as a recombinant protein vaccine in adjuvant or as a combined DNA prime-protein boost vaccine. All three vaccination formulations induced cross-reactive humoral and cell-mediated immune responses, although species-specific Th1 type T cell epitopes could be identified in both the NH2-terminal region and the COOH-terminal region of the antigens. This partial species-specificity was reflected in a higher--albeit not sustained--protective efficacy of the M. ulcerans than of the M. tuberculosis vaccine, particularly when administered using the DNA prime-protein boost protocol.

摘要

用编码来自牛型结核分枝杆菌卡介苗的 Ag85A 的质粒 DNA 进行免疫接种,可以部分保护 C57BL/6 小鼠免受随后的溃疡分枝杆菌足部挑战。不幸的是,这种交叉反应性保护不足以完全控制感染。尽管编码来自牛型结核分枝杆菌卡介苗(与结核分枝杆菌基因相同)和溃疡分枝杆菌的 Ag85A 的基因高度保守,但存在微小的序列差异,并且使用溃疡分枝杆菌的特定基因可能会导致更有效的疫苗。在这里,我们报告了在 C57BL/6 小鼠中比较结核分枝杆菌和溃疡分枝杆菌的 Ag85A 的免疫原性和保护效力,Ag85A 作为质粒 DNA 疫苗、佐剂中的重组蛋白疫苗或 DNA 初免-蛋白加强疫苗进行给药。所有三种疫苗制剂均诱导了交叉反应性体液和细胞介导的免疫应答,尽管在抗原的 NH2 末端和 COOH 末端区域都可以鉴定出种特异性 Th1 型 T 细胞表位。这种部分种特异性反映在溃疡分枝杆菌疫苗比结核分枝杆菌疫苗具有更高(尽管不是持续)的保护效力,尤其是在使用 DNA 初免-蛋白加强方案给药时。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/5cc8e4c8b2ba/pntd.0000199.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/e38b1d2af06c/pntd.0000199.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/e3dee4b7cb81/pntd.0000199.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/d6479bce5e1d/pntd.0000199.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/6d1eb2ae498d/pntd.0000199.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/716f4b3844b0/pntd.0000199.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/5cc8e4c8b2ba/pntd.0000199.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/e38b1d2af06c/pntd.0000199.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/e3dee4b7cb81/pntd.0000199.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/d6479bce5e1d/pntd.0000199.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/6d1eb2ae498d/pntd.0000199.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/716f4b3844b0/pntd.0000199.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dd1/2265439/5cc8e4c8b2ba/pntd.0000199.g006.jpg

相似文献

1
Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.通过同源蛋白加强,编码溃疡分枝杆菌(mycolyl-transferase Ag85A)的种特异性 DNA 疫苗的保护效力得到提高。
PLoS Negl Trop Dis. 2008 Mar 19;2(3):e199. doi: 10.1371/journal.pntd.0000199.
2
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.用编码结核分枝杆菌分支菌酸转移酶Ag85A的质粒DNA进行启动而非加强免疫,可增加接种卡介苗的小鼠在经静脉低剂量接种结核分枝杆菌H37Rv后的存活时间。
Vaccine. 2006 Apr 12;24(16):3353-64. doi: 10.1016/j.vaccine.2005.12.066. Epub 2006 Feb 6.
3
Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.卡介苗与表达ESAT-6和Ag85A融合蛋白的DNA疫苗初免-加强方案对小鼠结核病的免疫原性和保护效力
Clin Dev Immunol. 2011;2011:617892. doi: 10.1155/2011/617892. Epub 2011 Feb 27.
4
Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.表达溃疡分枝杆菌Ag85A的重组卡介苗对实验性布鲁里溃疡具有更强的保护作用。
PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0004046. doi: 10.1371/journal.pntd.0004046. eCollection 2015 Sep.
5
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.基于触发来自铜绿假单胞菌的OprI脂蛋白与分枝菌酸转移酶Ag85A融合体的Toll样受体的粘膜初免-加强疫苗接种用于结核病。
Immunol Lett. 2007 Jul 31;111(1):26-35. doi: 10.1016/j.imlet.2007.04.010. Epub 2007 May 22.
6
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.一种编码卡介苗牛分枝杆菌抗原85A的DNA疫苗对布鲁里溃疡的保护效力
Infect Immun. 2001 Sep;69(9):5403-11. doi: 10.1128/IAI.69.9.5403-5411.2001.
7
Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.编码溃疡分枝杆菌中九个分枝杆菌内酯聚酮合酶结构域的质粒DNA在感染小鼠中的疫苗潜力分析。
PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2604. doi: 10.1371/journal.pntd.0002604. eCollection 2014.
8
Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.溃疡分枝杆菌Ag85B-EsxH融合蛋白在重组卡介苗中的过表达提高了实验性布氏杆菌溃疡疫苗的效力。
PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005229. doi: 10.1371/journal.pntd.0005229. eCollection 2016 Dec.
9
Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.结合分枝菌酸转移酶Ag85A和磷酸盐转运受体PstS-3的结核DNA疫苗的免疫原性和保护效力
Immunology. 2006 Jul;118(3):321-32. doi: 10.1111/j.1365-2567.2006.02373.x.
10
Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.结核分枝杆菌中分枝菌酸转移酶Ag85A、Ag85B和Ag85C的小鼠Th1辅助性T细胞表位图谱
Infect Immun. 2003 Jan;71(1):483-93. doi: 10.1128/IAI.71.1.483-493.2003.

引用本文的文献

1
Unlocking Opportunities for and .为 和 解锁机会。
ACS Infect Dis. 2024 Feb 9;10(2):251-269. doi: 10.1021/acsinfecdis.3c00371. Epub 2024 Jan 31.
2
Multi-epitope vaccine candidates based on mycobacterial membrane protein large (MmpL) proteins against .基于分枝杆菌膜蛋白大(MmpL)蛋白的多表位疫苗候选物针对 。
Open Biol. 2023 Nov;13(11):230330. doi: 10.1098/rsob.230330. Epub 2023 Nov 8.
3
Identification of potential candidate vaccines against based on the major facilitator superfamily transporter protein.基于主要易化超家族转运蛋白鉴定针对 的潜在候选疫苗。

本文引用的文献

1
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.基于触发来自铜绿假单胞菌的OprI脂蛋白与分枝菌酸转移酶Ag85A融合体的Toll样受体的粘膜初免-加强疫苗接种用于结核病。
Immunol Lett. 2007 Jul 31;111(1):26-35. doi: 10.1016/j.imlet.2007.04.010. Epub 2007 May 22.
2
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).链霉素-利福平联合用药治疗布鲁里溃疡(溃疡分枝杆菌病)具有良好的临床疗效。
Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35. doi: 10.1128/AAC.00175-07. Epub 2007 May 25.
3
Front Immunol. 2022 Nov 8;13:1023558. doi: 10.3389/fimmu.2022.1023558. eCollection 2022.
4
Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against .重组Ag85B变体及其具有针对……的T细胞抗原活性的糖缀合物的合理设计、制备与表征
RSC Adv. 2018 Jun 26;8(41):23171-23180. doi: 10.1039/c8ra03535k. eCollection 2018 Jun 21.
5
Prediction of Epitopes in Virulence Proteins of for Vaccine Designing.用于疫苗设计的[病原体名称]毒力蛋白中表位的预测 。(原文中“for Vaccine Designing”前缺少具体病原体名称,翻译时补充了[病原体名称]以使句子完整通顺)
Curr Genomics. 2021 Dec 31;22(7):512-525. doi: 10.2174/1389202922666211129113917.
6
High antibody titres induced by protein subunit vaccines using antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice.使用热休克蛋白18(Hsp18)和MUL_3720抗原以及Toll样受体2(TLR-2)激动剂的蛋白质亚单位疫苗诱导产生的高抗体滴度不能保护小鼠免受布鲁里溃疡感染。
PeerJ. 2020 Aug 7;8:e9659. doi: 10.7717/peerj.9659. eCollection 2020.
7
The immunology of other mycobacteria: M. ulcerans, M. leprae.其他分支杆菌的免疫学:溃疡分枝杆菌、麻风分枝杆菌。
Semin Immunopathol. 2020 Jun;42(3):333-353. doi: 10.1007/s00281-020-00790-4. Epub 2020 Feb 25.
8
Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.在低剂量小鼠挑战模型中针对溃疡分枝杆菌感染的疫苗特异性免疫反应。
Infect Immun. 2020 Feb 20;88(3). doi: 10.1128/IAI.00753-19.
9
In Vivo Imaging of Bioluminescent : A Tool to Refine the Murine Buruli Ulcer Tail Model.活体生物发光成像:改良鼠型溃疡分枝杆菌尾模型的工具。
Am J Trop Med Hyg. 2019 Dec;101(6):1312-1321. doi: 10.4269/ajtmh.18-0959.
10
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.布鲁里溃疡,一种由溃疡分枝杆菌引起的与生态系统相关感染的原型。
Clin Microbiol Rev. 2017 Dec 13;31(1). doi: 10.1128/CMR.00045-17. Print 2018 Jan.
Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.
溃疡分枝杆菌毒素分枝杆菌内酯对树突状细胞功能的选择性抑制
J Exp Med. 2007 Jun 11;204(6):1395-403. doi: 10.1084/jem.20070234. Epub 2007 May 21.
4
Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.分枝杆菌内酯介导的对溃疡分枝杆菌感染的巨噬细胞肿瘤坏死因子产生的抑制作用对感染控制具有重要意义。
Infect Immun. 2007 Aug;75(8):3979-88. doi: 10.1128/IAI.00290-07. Epub 2007 May 21.
5
A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.
Infect Immun. 2007 May;75(5):2642-4. doi: 10.1128/IAI.01622-06. Epub 2007 Feb 26.
6
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer.从布氏溃疡病原体溃疡分枝杆菌基因组推断出的还原性进化和生态位适应
Genome Res. 2007 Feb;17(2):192-200. doi: 10.1101/gr.5942807. Epub 2007 Jan 8.
7
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.溃疡分枝杆菌巨噬细胞内生长阶段的证据。
Infect Immun. 2007 Feb;75(2):977-87. doi: 10.1128/IAI.00889-06. Epub 2006 Dec 4.
8
BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin.卡介苗对布氏杆菌溃疡的有效性:贝宁的一项病例对照研究。
Am J Trop Med Hyg. 2006 Oct;75(4):768-74.
9
Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.使用免疫显性的18千道尔顿小分子热休克蛋白作为暴露于溃疡分枝杆菌的血清学标志物。
Clin Vaccine Immunol. 2006 Dec;13(12):1314-21. doi: 10.1128/CVI.00254-06. Epub 2006 Oct 4.
10
Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F.全球分布的分枝杆菌属鱼类病原体产生一种新的质粒编码毒性大环内酯类物质——分支杆菌内酯F。
Infect Immun. 2006 Nov;74(11):6037-45. doi: 10.1128/IAI.00970-06. Epub 2006 Aug 21.